- Landmark research in Cell found that up to two-thirds of probiotic users show no meaningful gut colonization — the bacteria simply pass through (PMID 30193112).
- Human milk oligosaccharides (HMOs) don't need to colonize your gut — they work by feeding and amplifying the beneficial bacteria already living there.
- In a 100-person RCT, 77% of adults supplementing with HMOs showed significant increases in Bifidobacterium within just two weeks (PMID 27719686).
- HMOs also directly strengthen the gut barrier — research shows they may reduce gut permeability by approximately 40% and lower pro-inflammatory cytokine IL-6 (PMID 32933181).
- kēpos features kpHMO™, a proprietary HMO ingredient engineered to mirror the full oligosaccharide spectrum of breast milk — a fundamentally different approach from single-strain probiotics.
You've been taking your probiotic every morning. Maybe even a high-count, multi-strain formula. And yet — the bloating persists. The irregularity lingers. Your gut still doesn't feel quite right.
Here's what the science is quietly saying: probiotics may not be working the way you think they are. And if you've ever wondered why your gut health hasn't shifted despite months of supplementation, the answer likely isn't that you need a better probiotic. It's that probiotics are designed to solve the wrong problem.
This isn't just a marketing claim. It's a story backed by some of the most rigorous gut microbiome research published in the last decade — and it's the reason why a new class of gut health compounds, human milk oligosaccharides (HMOs), is generating serious scientific excitement.
The Colonization Problem: Why Most Probiotics Don't Stick
The fundamental premise of probiotic supplementation is appealing: consume beneficial bacteria, and those bacteria will take up residence in your gut, outcompeting harmful microbes and shifting your microbiome toward better health. It's a logical idea. But it rests on an assumption the data doesn't always support.
In 2018, researchers at the Weizmann Institute of Science published a landmark study in Cell that fundamentally challenged this model. Using endoscopic sampling — actually measuring bacterial populations at the mucosal lining of the gut — they found something striking: up to two-thirds of participants were "resisters" whose guts simply expelled the probiotic strains without meaningful colonization (Zmora et al., 2018, PMID 30193112). The bacteria passed through and left no lasting mark.
The same research group published a companion paper in the same issue of Cell with an even more provocative finding: in adults who had just completed a course of antibiotics — a moment when the gut is theoretically most "open" to new bacterial colonizers — probiotic supplementation significantly delayed the restoration of the natural microbiome compared to people who recovered spontaneously (Suez et al., 2018, PMID 30193113). In other words, probiotics sometimes got in the way of recovery.
This doesn't mean probiotics are worthless. For certain clinical applications — specific IBS subtypes, antibiotic-associated diarrhea prevention — particular strains have demonstrated real benefit. But the daily, generic "gut health" probiotic that millions of people take every morning? The evidence for lasting, measurable microbiome change is much thinner than the marketing suggests.
What Probiotics Are Actually Fighting Against
Understanding why probiotics struggle requires understanding your existing gut ecosystem. Your gut is home to roughly 38 trillion bacteria representing hundreds of species — a community so complex, diverse, and entrenched that it has co-evolved with your body over your entire lifetime. This community doesn't welcome outsiders casually.
Your gut microbiome has what researchers call "colonization resistance" — an inherent ability to prevent foreign bacteria from establishing a foothold. This is actually a protective feature; it's why pathogenic bacteria don't typically take over your gut every time you're exposed to them. But that same resistance applies to the strains in your probiotic capsule.
When you swallow a probiotic, those bacteria face acid in your stomach, bile salts in your small intestine, and then — if they survive — an intensely competitive environment populated by trillions of bacteria that have spent years establishing territorial dominance over every available nutrient and attachment site. Most probiotic strains don't have a competitive advantage in an adult gut. They were selected because they're safe and stable to manufacture, not because they're particularly well-suited to colonizing a mature human microbiome.
HMOs Bypass the Colonization Problem Entirely
Here's where human milk oligosaccharides take a fundamentally different approach — and why the comparison to probiotics isn't really even apples-to-apples.
HMOs don't try to add new bacteria to your gut. They transform the environment that shapes which bacteria already there can thrive.
HMOs are complex carbohydrates — dietary fibers with an unusually sophisticated structure — that your digestive enzymes cannot break down. They arrive in the colon intact and become an exclusive food source for specific beneficial bacteria, particularly Bifidobacterium species and certain Lactobacillus strains. These are bacteria that already live in your gut. HMOs don't need to colonize anything. They simply make your existing beneficial microbes more competitive.
The effect, as documented in research, is measurable and rapid. In a randomized controlled trial of 100 healthy adults, HMO supplementation led to significant increases in Bifidobacterium populations in 77% of participants within just two weeks — without adding any external bacteria (Elison et al., 2016, PMID 27719686). That's your own gut ecosystem reshaping itself around a new fuel source.
No colonization resistance to overcome. No survival gauntlet through stomach acid. No competition with 38 trillion established residents. HMOs work with your microbiome, not against it.
The Gut Barrier Advantage That Probiotics Rarely Address
Beyond their prebiotic function, HMOs do something else that most probiotics cannot claim: they directly support the integrity of your gut lining.
Your gut barrier is a single-cell-layer wall separating your intestinal contents from your bloodstream. When that barrier becomes permeable — commonly called "leaky gut" — bacterial fragments and food antigens can slip through, triggering immune activation and chronic low-grade inflammation. This underlies many of the gut symptoms people hope to address with probiotics: bloating, discomfort, immune dysregulation.
Research published in Nutrients found that HMOs may reduce gut permeability by approximately 40%, significantly decrease the pro-inflammatory cytokine IL-6, and upregulate tight-junction proteins — the molecular "glue" that holds gut lining cells together (Šuligoj et al., 2020, PMID 32933181). These are direct, structural effects on the gut wall — not just an indirect consequence of microbiome changes.
Most probiotic research focuses on microbiome composition shifts. HMOs are working on a parallel, complementary track: reinforcing the physical architecture of the gut barrier at the same time.
What kpHMO™ Brings to This Science
Understanding the promise of HMOs raises a natural question: how do you supplement with them effectively?
This is where the quality of the HMO source matters significantly. Breast milk doesn't contain a single HMO. It contains a spectrum — over 150 distinct oligosaccharide structures that collectively shape the infant microbiome across multiple bacterial populations and multiple mechanisms simultaneously. The diversity appears to be part of what makes the system work.
kēpos is formulated around kpHMO™, a proprietary HMO ingredient designed to mirror that full oligosaccharide spectrum — covering all neutral, fucosylated, and sialylated HMO bases. Unlike single-strain HMO supplements that isolate one structure, kpHMO™ is engineered to replicate the compositional complexity of actual breast milk oligosaccharides, giving your gut the full range of substrates that beneficial bacteria can selectively ferment.
This isn't a conceptual difference — it reflects the way HMO science is evolving. The research on HMO diversity in adult populations consistently points toward the importance of spectrum, not just dose. And kpHMO™ is purpose-built for that standard.
kēpos also pairs kpHMO™ with effera™ recombinant human lactoferrin — a key immune and iron-transport protein found in breast milk alongside HMOs. The combination reflects how these compounds appear in nature: working together, not in isolation.
The Bottom Line on Probiotics vs. HMOs
Probiotics work by importing bacteria into an environment that often resists them. HMOs work by transforming an environment so the bacteria already there flourish. These are genuinely different mechanisms — and for many people, the mechanism that doesn't require overcoming colonization resistance may produce more consistent results.
The research isn't saying throw out your probiotic. For specific, well-documented applications, certain strains still have a meaningful evidence base. But if you're taking a probiotic for general daily gut support and not seeing results, the issue may not be the brand or the count — it may be the approach.
HMOs offer a fundamentally different architecture for gut health: prebiotic precision, gut barrier support, and a mechanism designed around your biology rather than in spite of it. That's the case for rethinking what "gut health" supplementation can actually look like.
Explore kēpos and the science behind kpHMO™ at trykepos.com.
Frequently Asked Questions
Can I take HMOs alongside my probiotic?
Yes — HMOs and probiotics work through different mechanisms, and there's no evidence of conflict between them. HMOs act as prebiotics that selectively feed beneficial bacteria; if your probiotic strains do manage to establish in your gut, HMOs may actually provide a more favorable environment for them. That said, many people find that HMOs alone deliver the microbiome shift they were hoping their probiotic would provide.
Why do two-thirds of people not benefit from probiotics?
Your gut microbiome is highly personalized — shaped by decades of diet, environment, and genetics. Research from the Weizmann Institute suggests that individual variation in gut "colonization resistance" determines whether probiotic strains can establish in mucosal tissue. People classified as "resisters" have microbiome configurations that simply don't leave room for incoming bacterial strains (PMID 30193112). HMOs sidestep this entirely because they don't require colonization.
How quickly do HMOs produce results?
In the 100-adult RCT conducted by Elison et al., measurable increases in Bifidobacterium populations were observed within two weeks of HMO supplementation (PMID 27719686). Individual timelines vary based on your baseline microbiome composition, but HMOs are considered fast-acting relative to other microbiome interventions because they work with existing bacterial populations rather than trying to introduce new ones.
What makes kpHMO™ different from other HMO supplements?
kpHMO™ is a proprietary HMO ingredient formulated to cover the full range of oligosaccharide structures found in breast milk — including neutral, fucosylated, and sialylated HMOs. Most commercially available HMO supplements feature a single isolated HMO structure. kpHMO™ is designed to replicate compositional diversity, which research suggests is important for comprehensively supporting multiple beneficial bacterial populations simultaneously.
Are HMOs just for babies?
HMOs were first studied in the context of infant nutrition, but the science on adult applications has grown substantially. Multiple RCTs in healthy adults have confirmed that HMO supplementation meaningfully shifts adult gut microbiota, supports gut barrier integrity, and is well tolerated. The same biological machinery that makes HMOs work in infants — selective fermentation by Bifidobacterium, direct gut barrier effects — is present and active in adults.
